Cancer and its therapies have mild, but debilitating effects on cognitive function. Approximately 75% of cancer patients report cognitive deficits during treatment and up to 35% of people report cognitive impairment years following the completion of therapy. With more than 14M cancer survivors in the United States, roughly 5M people are living with long-term cognitive deficits.
As the incidence of cancer increases due to an aging population, and prevalence grows due to improved survivorship, more emphasis is being placed on the preservation of cognitive health and quality of life both during and post-treatment.
Miro provides precise, universally accessible tools that can precisely describe changes in the cognition of cancer patients and cancer survivors over time. This not only supports the innovative development of new therapies that preserve cognition, but aids in the determination cognitive interventions that might protect patients from the negative effects of cancer therapies, and support the personalization of cancer care by predicting and pro-actively intervening in the treatment of patients who may be at high-risk for "chemo brain".